{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:42:02Z","timestamp":1775886122891,"version":"3.50.1"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,6,21]]},"DOI":"10.1001\/jama.2022.9846","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T15:01:17Z","timestamp":1655823677000},"page":"2281","source":"Crossref","is-referenced-by-count":28,"title":["Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment"],"prefix":"10.1001","volume":"327","author":[{"given":"Rita","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2793470\/jama_rubin_2022_fd_220029_1655316057.8387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T15:01:18Z","timestamp":1655823678000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2793470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":0,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,6,21]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.9846","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}